-
The Instruction of Chlorprothixene hydrochloride
Time of Update: 2023-05-10
The manufacturing process for chlorprothixene hydrochloride involves several steps, including synthesis, purification, and formulation.
The manufacturing process for chlorprothixene hydrochloride involves several steps, including synthesis, purification, and formulation.
The manufacturing process for chlorprothixene hydrochloride involves several steps, including synthesis, purification, and formulation.
-
Newly discovered inhibitor for the treatment of B-cell lymphoma
Time of Update: 2021-11-14
Image: Evaluation of the anti-tumor efficacy of IHMT-EZH2-115 in a xenograft mouse modelRecently, researchers led by Professor Liu Qingsong, Hefei Institute of Material Science, Chinese Academy of Sciences, discovered an effective selective zeste homolog 2 (EZH2) enhancer inhibitor ihht-EZH2-115 for the treatment of b-cell lymphoma .
-
ED drugs can prolong life and prevent heart disease
Time of Update: 2021-07-13
After comparing alprostadil with various PDE5 inhibitors, the study found that if men take PDE5 inhibitors for ED while treating stable coronary artery disease, they can not only reduce the risk of new heart attacks, but also It can also extend life expectancy .
-
Open the Rainbow Gate to New Natural Colors
Time of Update: 2021-02-16
"We have developed formulations from three unique natural blue resources, including spirulina, and patents are pending, allowing us to offer our customers superior blue, green and purple pigments that can be used in all food and beverage applications.
-
Myeloma cells are gone! The results of animal experiments on antisant oligonucleotide therapy were positive
Time of Update: 2021-02-11
Researchers at the University of California, San Diego (UCSD) School of Medicine and Ionis Pharmaceuticals are using a new targeted therapy to treat multiple myeloma.
they used anisotym oligonucleotides (ASOs) to silence the IRF4 gene associated with the proliferation of myeloma progenito cells and tumor cells, and achieved positive results in animal experiments.
-
The first Phase 3 clinical trial of DMD gene therapy completed the first patient's medication
Time of Update: 2021-01-12
Dr. Brenda Cooperstone, Pfizer's Chief Development Officer for Rare Diseases, said, "We believe that this gene therapy, if successful and approved in Phase 3 clinical trials, has the potential to significantly improve the trajectory of DMD disease progression, and we are working with global regulators to launch this project as soon as possible in other countries." : This article is intended to introduce medical and health research, not treatment options recommended.
-
Drug kickbacks hit two in a hit! The Supreme Law and the Health Insurance Bureau signed a memorandum of cooperation
Time of Update: 2020-10-02
" The relevant person in charge of the price recruitment department of the State Medical Security Administration stressed in response to a reporter's question that in order to obtain the information of the source of the case in a timely, accurate and complete manner, the State Health Insurance Administration will actively promote the overall cooperation of the departments and explore the establishment of exchanges and policy linkage mechanisms with the courts, taxation, market supervision and other departments.
-
Long: Chinese preparations export dragon's plight
Time of Update: 2020-08-01
now we see the dawn of "domestic medicine" in line with international standards, but before that those not recognized, the drop of the course, need to invest in a country's medical resources and a long time to make up, but the past mistakes have led to the Chinese preparations in the process of going abroad facing the "three mountains" - GMP inspection (Technical Dossiers for License), cost (CoGS) trouble.
-
Express . . . Reducing the risk of disease progression in patients with triple-negative breast cancer was reduced by 59%, and innovative antibody conjugate drugs reached stage 3 clinical endpoint
Time of Update: 2020-07-18
▎ immunomedics announced today that troldvy (sacituzumab govitecan hziy), an antibody coupled drug developed by the company, has reached the primary end point of progression free survival (PFS) in a confirmatory phase 3 ascent clinical trial for patients with metastatic triple negative breast cancer (mtnbc), reducing the risk of disease progression or death by 59%.
-
FDA approves Xeris ready-to-use glutagon Gvoke injection application
Time of Update: 2020-06-08
recently, Xeris Pharmaceuticals announced that FDA (http:// approved its application for a market application for a ready-to-use glucagon Gvoke injection to treat severe hypoglycemia Gvoke has t
-
Pharmaceutical intelligence data enterprise version 1.2 & Pharmaceutical intelligence data app2.2 strong new
Time of Update: 2019-04-16
In April, the world is full of flowers Yaozhi data enterprise edition and Yaozhi app will bring you different new experiences in this warm spring More than ten databases have been added to the latest
-
A major breakthrough in the internationalization of traditional Chinese medicine: Tongxinluo in the treatment of vascular diseases
Time of Update: 2019-04-01
The results of "a randomized, double-blind, placebo-controlled, multicenter clinical study on the application of Tongxinluo in the intervention of carotid plaque" led by academician Zhang Yun of Qilu
